Myeloproliferative Neoplasms | Specialty

The myeloproliferative neoplasms condition center is a comprehensive resource for clinical news on myeloproliferative neoplasms. Read more at OncLive.

Consensus on Clinical Trial End Points Is Essential for Improved Drug Development Across MPNs

August 11th 2025

Andrew Kuykendall, MD, outlines the limitations of current clinical end points and discusses the need for molecularly informed drug development in MPN.

Dr Kremyanskaya on the Efficacy of Divesiran in Polycythemia Vera

August 8th 2025

Marina Kremyanskaya, MD, PhD, discusses safety and early efficacy findings with divesiran in polycythemia vera.

Five Under 5: Top Oncology Videos for the Week of 7/27

August 3rd 2025

The top 5 OncLive videos of the week cover insights in lung cancer, myelofibrosis, and mantle cell lymphoma.

EMA Grants Orphan Drug Designation to Nuvisertib for Myelofibrosis

August 2nd 2025

Nuvisertib has received orphan drug designation from the EMA for patients with myelofibrosis.

Hemoglobin Improvement With Momelotinib Confers OS Benefit in Myelofibrosis With Anemia

July 31st 2025

Francesca Palandri, MD, PhD, discusses findings from a post hoc analysis of momelotinib-induced hemoglobin level improvements in myelofibrosis with anemia.

IMproveMF Trial Shows Early Potential of Imetelstat Plus Ruxolitinib in Myelofibrosis

July 30th 2025

John Mascarenhas, MD, discusses early findings from the IMproveMF trial combining imetelstat with ruxolitinib in intermediate- to high-risk myelofibrosis.

Dr Mascarenhas on Key Considerations for Clinical Trial Enrollment in Myelofibrosis

July 29th 2025

John O. Mascarenhas, MD, discusses important factors to consider when evaluating patients for clinical trial enrollment in myelofibrosis.

Dual SVR/TI Response With Momelotinib Confers OS Benefit in Myelofibrosis With Anemia and Low Platelet Counts

July 29th 2025

Francesca Palandri, MD, PhD, discusses the results from a subgroup analysis of momelotinib vs ruxolitinib in myelofibrosis with anemia and low platelet counts.

IHC Testing Could Serve as Surrogate to NGS for Early Detection of TP53-Mutant MDS/AML

July 29th 2025

Results of an observational study showed that immunohistochemistry could act as a biomarker for the early detection of TP53‐mutant MDS or AML.

IMpact-MF Trial Aims to Show OS Benefit of Imetelstat in Relapsed Myelofibrosis

July 29th 2025

John Mascarenhas, MD, discusses the rationale for evaluating imetelstat in patients with relapsed/refractory myelofibrosis.

Dr Patel on the p53 IHC Positivity as Potential Surrogate for Multi-Hit TP53 Mutations in MDS and AML

July 25th 2025

Shyam A. Patel, MD, PhD, discusses the threshold of p53 IHC positivity best correlating with multi-hit TP53 mutational status in MDS and AML.

Dr Gerber on the Benefits of p53 IHC Testing for Identifying TP53-Mutant MDS and AML in Underserved Regions

July 25th 2025

Jonathan M. Gerber, MD, discusses the potential implementation of p53 IHC testing for MDS and AML in regions with limited access to NGS.

IHC Testing May Enable Expedited Identification of TP53-Mutant MDS and AML

July 24th 2025

Shyam A. Patel, MD, PhD, and Jonathan M. Gerber, MD, discuss the use of IHC testing for earlier identification of TP53 mutations in MDS and AML.

Evolution of MDS Management Hinges on Standardized Disease Classification, Molecularly Informed Risk Stratification

July 22nd 2025

Hetty E. Carraway, MD, MBA, highlights the evolving molecular classification of MDS and novel agents in the therapeutic arsenal.

Integrating Luspatercept Into Clinical Practice and Community Settings in ESA-Naive Lower-Risk MDS

July 22nd 2025

Guillermo Garcia-Manero, MD, discusses the integration of luspatercept into real-world practice in ESA-naive, lower-risk MDS.

Dr Komrokji on the Clinical Integration of Imetelstat for Lower-Risk MDSLR-MDS

July 22nd 2025

Rami Komrokji, MD, shares advice on how to integrate imetelstat into clinical practice for transfusion-dependent lower-risk myelodysplastic syndromes.

The OncFive: Top Oncology Articles for the Week of 7/13

July 19th 2025

Glofitamab received a CRL from the FDA in R/R DLBCL, ODAC voted against belantamab mafodotin in R/R multiple myeloma, and more.

Luspatercept Plus Concomitant JAK Inhibitor Therapy Misses Primary End Point in Myelofibrosis-Associated Anemia

July 18th 2025

Luspatercept plus a concomitant JAK inhibitor didn’t meet the primary end point of 12-week RBC transfusion independence in myelofibrosis-associated anemia.

IHC Testing Leads to Early Detection of TP53-Mutant AML and MDS: With Jonathan M. Gerber, MD; and Shyam A. Patel, MD, PhD

July 16th 2025

Drs Gerber and Patel discuss a study they conducted investigating the use of IHC as a biomarker for early TP53 mutation identification in MDS and AML.

Data for Elotuzumab Support Further Investigation in JAK Inhibitor–Based Combinations in Myelofibrosis

July 15th 2025

Safety and efficacy data for elotuzumab support its further investigation in the treatment of myelofibrosis.